건강보험 약품비 증가의 주요 요인분석
Major Growths of Korean Pharmaceutical Expenditure
0
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Objectives: Rising pharmaceutical expenditure in Korea has become a major concern of policy makers over recent years. To reduce the growth in pharmaceutical expenditure, we need to analyze the major determinants of pharmaceutical spending. We defined three drug types: new, abandoned and existing drugs. The existing drugs are composed of two aspects - the changes in price and quantity Methods: The data was extracted from the Korean National Health Insurance (NHI) claims data. The data was based on every prescription product dispensed to beneficiaries of the NHI between 2002 and 2006. Results: The contribution of the new drugs was 22∼48% in the first half of 2002∼2006. Abandoned products were associated with cost decrease. The contribution of the existing products impacted on most of the growth of the paired years in 2002∼2006. The existing product spending broke down into price and quantity effects. Price Changes (PC) had the range of -1.7 to 0.5. Quantity Changes (QC) was more than 9% in 2002∼2006. Recently, the number of prescription affected more than the mix of prescription on the QC. Conclusions: The results of this study provide evidence for making the political decision that the pharmaceutical regulations in Korea need to be focused on the volume control.
Abstract
Objectives: Rising pharmaceutical expenditure in Korea has become a major concern of policy makers over recent years. To reduce the growth in pharmaceutical expenditure, we need to analyze the major determinants of pharmaceutical spending. We defined three drug types: new, abandoned and existing drugs. The existing drugs are composed of two aspects - the changes in price and quantity Methods: The data was extracted from the Korean National Health Insurance (NHI) claims data. The data was based on every prescription product dispensed to beneficiaries of the NHI between 2002 and 2006. Results: The contribution of the new drugs was 22∼48% in the first half of 2002∼2006. Abandoned products were associated with cost decrease. The contribution of the existing products impacted on most of the growth of the paired years in 2002∼2006. The existing product spending broke down into price and quantity effects. Price Changes (PC) had the range of -1.7 to 0.5. Quantity Changes (QC) was more than 9% in 2002∼2006. Recently, the number of prescription affected more than the mix of prescription on the QC. Conclusions: The results of this study provide evidence for making the political decision that the pharmaceutical regulations in Korea need to be focused on the volume control.
참고문헌 (24)
- OECD, "Pharmaceutical policies in OECD countries: reconciling social and industrial goals", pp.2000, OECD DEELSA
- OECD, "Pharmaceutical pricing polices in a global market", ~ (2008)
- Morgan SG, "Quantifying components of drug expenditure inflation: the British Columbia seniors’ drug benefit plan", Health Serv Res, 37, pp.1243~1266 (2002)
- OECD, "Health at a glance 2009, OECD indicators", ~ (2009)
- Okunade, AA, "The pervasiveness of pharmaceutical expenditure inertia in the OECD countries", Social Science & Medicine Elsevier, 63(1), pp.225~238 (2006)
- Morgan SG, "Booming prescription drug expenditure: a population-based analysis of age dynamics", Med Care, 43(10), pp.996~1008 (2005)
- Chernew ME, "Pharmaceutical cost growth under capitation", Health Aff, 19(6), pp.266~276 (2000)
- Chernew ME, "Decomposing pharmaceutical vost growth in different types of health plans", American Journal of Managed Care, 7(7), pp.667~673 (2001)
- Mrazek MF, "Comparative approaches to pharmaceutical price regulation in the European Union", Croatian Medical Journal, 43(3), pp.453~461 (2002)
- "Patented Medicine Prices Review Board. annual report" (2009)[URL]
- Henriksson F, "Pharmaceutical expenditure in Sweden", Health Policy, 47, pp.125~144 (1999)
- Frank RG, "Measuring prices and quantities of treatment for depression", Am Econ Rev, 88(2), pp.106~ (1998)
- Berndt ER, "Pharmaceuticals in U.S health care: Determinants of quantity and price", Journal of Economic Perspective, 16(4), pp.45~66 (2002)
- Dubois RW, "Explaining drug spen-ding trends: Does perception match reality", Health Aff, 19(2), pp.231~239 (2000)
- Berndt ER, "The U.S. pharmaceutical industry: why major growth in times of cost containment", Health Aff, 20, pp.100~114 (2001)
- 약제비 적정화를 위한 요인 분석, "최윤정", 건강보험심사평가원, ~ (2007)
- 허순임, "합리적 약제비 지출 방안 연구" (2006), 국민건강보험공단
- 최윤정, "보험약가 상환방식 연구" (2009), 건강보험 심사평가원
- U.S. Department of Commerce, "International Trade Administration. Pharmaceutical Price Controls in OECD Countries: Implication for U.S. consumers, pricing, research and development, and innovation" (2004)
- Prescription Drugs Expenditures in 2001: Another Year of Escalating Costs, "National Institute for Health Care Management Foundation (NHICM)", ~
- "PHARMAC Annual Plan 2004", 5. New Zealand, 2005
- 정형선, "실거래가상환제의 건강보험재정에 관한 영향", 보건행정학회지, 15(3), pp.40~59 (2005), 한국보건행정학회
- 약품비구성 요소별 기여율 분석, "배은영", 건강보험심사평가원, ~ (2007)
- Danzon PM, "International price and availability of pharmaceuticals in 2005", Health Affaire, 27(1), pp.221~233 (2008)